...Zhoujunyi Tian; Jin Zhang; Deruo Liu; Chaoyang Liang Introduction: There remain controversies about the role of surgery for N3 stage non-small cell lung cancer (NSCLC) patients. Methods: N3 stage NSCLC patients were identified from the US National Cancer Institute Surveillance, Epidemiology...

...Ahmed A. Refae; Rafat I. Abu Shakra; Ezzeldin M. Ibrahim Introduction: Patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations face poor outcomes after progression on tyrosine kinase inhibitors (TKIs). The efficacy of immune checkpoint inhibitors...

... death ligand 1 (PD-L1) antibodies and platinum-based chemotherapy has been widely used as a first-line treatment for patients with unresectable advanced non-small cell lung cancer (NSCLC) in clinical settings; however, prognostic biomarkers associated with survival outcomes have not been sufficiently...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Non-small cell lung cancer Immune checkpoint inhibitor...

... recurrence Chemotherapy Non-small cell lung cancer Epidermal growth factor receptor-tyrosine kinase inhibitor Immune checkpoint inhibitor Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for more than 80% of all cases [ 1...

...Nozomu Motono; Takaki Mizoguchi; Masahito Ishikawa; Shun Iwai; Yoshihito Iijima; Hidetaka Uramoto Introduction: It is unclear whether a lower lobe origin is a risk factor for early recurrence of non-small cell lung cancer (NSCLC) in patients who underwent pulmonary resection. Methods: The risk...

... III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CRT). However, the duration of immune consolidation and the efficacy and safety of different immune agents remain unclear. We conducted a systematic review of relevant studies. Methods: We searched all the relevant studies...

...Huanshun Wen; Chaoyang Liang Introduction: The objective of this study was to compare the survival after lobectomy (LR) and sub-lobar resection (SLR) of the left upper lobe (LUL) among non-small cell lung cancer (NSCLC) patients with stage IA. Methods: This retrospective cohort research analyzed...

...Derek De-Rui Huang; Bin-Chi Liao; Wei-Hsun Hsu; Ching-Yao Yang; Yen-Ting Lin; Shang-Gin Wu; Tzu-Hsiu Tsai; Kuan-Yu Chen; Chao-Chi Ho; Wei-Yu Liao; Jin-Yuan Shih; Chong-Jen Yu; James Chih-Hsin Yang; Ann-Lii Cheng; Ying-Chun Shen Introduction: In real-world practice, most non-small cell lung cancer...

... Kagamu Introduction: Pembrolizumab (Pemb) therapy in conjunction with carboplatin and paclitaxel (PTX)/nab-PTX has been efficacious in treating non-small cell lung cancer (NSCLC). However, the response predictors of this combination therapy (Pemb-combination) remain undetermined. We aimed to evaluate...

... been reported to be associated with prognosis in multiple cancers. This study aimed to investigate the association of polymorphisms in lipid metabolism pathway genes with survival outcomes in patients with surgically resected non-small cell lung cancer (NSCLC). Methods: In total, 744 patients...

...Nozomu Motono; Takaki Mizoguchi; Masahito Ishikawa; Shun Iwai; Yoshihito Iijima; Hidetaka Uramoto Introduction: Although the consolidation diameter of a tumor on computed tomography (CT) is an adaptation criterion for limited resection in early-stage non-small cell lung cancer (NSCLC), whether...

... value of a newly found circRNA VPS35L (circVPS35L) as a biomarker for the diagnosis of non-small cell lung cancer (NSCLC). Methods: Reverse-transcription quantitative PCR (RT-qPCR) was used to determine the expression levels of circVPS35L in tissues, whole blood, and cell lines. The actinomycin D assay...

...)-tyrosine kinase inhibitors (TKIs) are the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with sensitive EGFR mutations. The Glasgow prognostic score (GPS) is an inflammation-assessing score based on C-reactive protein and albumin concentrations. Information regarding...

... of the effectiveness of immune checkpoint inhibitor (ICI) monotherapy in previously treated patients with non-small cell lung cancer (NSCLC) remain ill-defined. We investigated whether the Glasgow prognostic score (GPS) could serve as such predictors. Methods: Eighty patients treated with pembrolizumab or atezolizumab...

...Walid Shalata; Alexander Yakobson; Sarah Weissmann; Elron Oscar; Muhammed Iraqi; Waleed Kian; Nir Peled; Abed Agbarya Introduction: Non-small cell lung cancer (NSCLC) accounts for most lung cancers and is a leading cause of cancer-related deaths in the USA. Alterations in c-MET, a tyrosine kinase...

... DNA (cfDNA) provides a noninvasive method for early detection of patient progression. We investigated whether the genetic dynamics detected in cfDNA during treatment can act as a predictive or prognostic marker of outcome. Methods: Patients with advanced EGFR -mutated non-small cell lung cancer (NSCLC...

... the treatment paradigm of advanced non-small cell lung cancer (NSCLC). However, for those who are not eligible for such therapy or currently have no available standard treatment options, new precision treatment approaches are needed. Human trophoblast cell-surface antigen 2 (TROP2) is a transmembrane...

... and editing, supervision, and resources. References 1. Garon   EB , Hellmann   MD , Rizvi   NA , Carcereny   E , Leighl   NB , Ahn   M-J ,   Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE...

... ( n = 24). The overall response rate was 45.8%, and the disease control rate was 74.4%. Table 1. Baseline patient characteristics at the start of first-line treatment First-line treatment Immune checkpoint inhibitor Non-small cell lung cancer Overall survival Pembrolizumab Post...